ストックスクリーナーアプリを入手
31.00
2.45%
0.74
前日終値:
$30.26
開ける：
$30.92
24時間の取引高:
1.95M
Relative Volume:
3.00
時価総額：
$1.93B
収益：
$32.08M
当期純損益:
$-169.77M
株価収益率:
-10.91
EPS:
-2.8418
ネットキャッシュフロー:
$-147.70M
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
+6.79%
6か月 パフォーマンス:
-2.91%
1年 パフォーマンス:
+167.93%
1日の値動き範囲:
$29.84
$31.53
1週間の範囲:
$28.95
$31.53
52週間の値動き範囲:
$11.17
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.00 | 1.93B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-02-05 | 開始されました | Guggenheim | Buy |
| 2026-01-05 | 再開されました | Chardan Capital Markets | Buy |
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Understanding the Setup: (STOK) and Scalable Risk - Stock Traders Daily
Stoke Therapeutics general counsel sells $43,637 in common stock By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel sells $43,637 in common stock - Investing.com
Insider Sell Alert: Jonathan Allan Sells Shares of Stoke Therape - GuruFocus
Stoke Therapeutics (STOK) legal chief sells 1,457 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Granahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 16, 2026 - BioSpace
Insider sales at STOK (NASDAQ: STOK) list 27,481 shares in March 2026 - Stock Titan
Stoke Therapeutics Stock (US86150R1023): Analyst Sentiment and Valuation Come Into Focus - AD HOC NEWS
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6%Should You Buy? - MarketBeat
STOK: Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028 - TradingView
Stoke Therapeutics (STOK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
The Technical Signals Behind (STOK) That Institutions Follow - Stock Traders Daily
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options - Stock Titan
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Stoke Therapeutics (STOK) director granted 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike - Stock Titan
Stoke Therapeutics (STOK) director granted options to buy 17,786 shares - Stock Titan
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Stoke Therapeutics Stockholders Approve Directors and Governance Items - TipRanks
Stoke Therapeutics (NASDAQ: STOK) 2026 meeting elects all directors - Stock Titan
STOK: Lead therapy delivers durable seizure and cognitive benefits, with pivotal data due mid-2027 - TradingView
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stoke Therapeutics Advances Dravet Syndrome Clinical Trials Following Positive Results - asatunews.co.id
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates - Insider Monkey
Stoke Therapeutics (STOK) Pulls Back: Support Test Looms After 2.21% DeclineMoving Average Crossovers - The Legal Advocate
STOK Analyst Consensus - Investing.com Australia
STOK Corporate Insider Activity - Investing.com Australia
Stoke Therapeutics to Present at Upcoming Investor Conferences in June - Business Wire
Precision Trading with Stoke Therapeutics Inc. (STOK) Risk Zones - Stock Traders Daily
Stoke Therapeutics (STOK) Edges Lower: Mixed Signals Near Key ResistanceInstitutional Sentiment - The Legal Advocate
UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Nathan Lee Starts New Role as Vice President, Commercial Manufacturing at Stoke Therapeutics - hrtoday.in
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed - simplywall.st
Zorevunersen tied to long-term benefits in Dravet syndrome - Dravet Syndrome News
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):